Search

Your search keyword '"Finlay M"' showing total 1,296 results

Search Constraints

Start Over You searched for: Author "Finlay M" Remove constraint Author: "Finlay M"
1,296 results on '"Finlay M"'

Search Results

57. Correction to “Discovery of a Thiadiazole–Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models”

60. Constant 4He Concentration and 190Pt‐4He age of Detrital Pt‐Alloy Grains from the Santiago River, Ecuador: Potential as a 4He Mineral Reference Material.

65. Supplementary Figure 1 from Novel Arginase Inhibitor, AZD0011, Demonstrates Immune Cell Stimulation and Antitumor Efficacy with Diverse Combination Partners

66. Supplementary Table 1 from Novel Arginase Inhibitor, AZD0011, Demonstrates Immune Cell Stimulation and Antitumor Efficacy with Diverse Combination Partners

67. Supplementary Figure 3 from Novel Arginase Inhibitor, AZD0011, Demonstrates Immune Cell Stimulation and Antitumor Efficacy with Diverse Combination Partners

68. Supplementary Figure 4 from Novel Arginase Inhibitor, AZD0011, Demonstrates Immune Cell Stimulation and Antitumor Efficacy with Diverse Combination Partners

69. Supplementary Figure 5 from Novel Arginase Inhibitor, AZD0011, Demonstrates Immune Cell Stimulation and Antitumor Efficacy with Diverse Combination Partners

70. Supplementary Figure 2 from Novel Arginase Inhibitor, AZD0011, Demonstrates Immune Cell Stimulation and Antitumor Efficacy with Diverse Combination Partners

71. Data from Novel Arginase Inhibitor, AZD0011, Demonstrates Immune Cell Stimulation and Antitumor Efficacy with Diverse Combination Partners

72. Novel Arginase Inhibitor, AZD0011, Demonstrates Immune Cell Stimulation and Antitumor Efficacy with Diverse Combination Partners

73. Supplementary Figure 3 from AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

74. Data from Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions

75. Supplementary Table 1 from AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

76. Supplementary Figure 1 from AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

77. Supplementary Figures 1-8 from Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions

78. Supplementary Figure 7 from AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

79. Supplementary Figure 4 from AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

80. Supplementary Figure 5 from AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

81. Supplementary Figure 6 from AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

82. Supplementary Figure 2 from AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

83. Data from AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

84. Supplementary Data from Preclinical Comparison of the Blood–brain barrier Permeability of Osimertinib with Other EGFR TKIs

85. Figure S1 from Preclinical Comparison of the Blood–brain barrier Permeability of Osimertinib with Other EGFR TKIs

86. A topographic hinge-zone divides coastal and inland ice dynamic regimes in East Antarctica

88. The total synthesis of the bicyclic acetal core of zaragozic acid C

89. The Winchcombe meteorite, a unique and pristine witness from the outer solar system

90. Small Molecule Inhibitors of the Epidermal Growth Factor Receptor

91. Dispersion aspects of periodically amplified soliton transmission systems

92. AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity

93. Adrenal tumours in patients with pathogenic APC mutations: a retrospective study

95. Multi-Isotope Geochemical Baseline Study of the Carbon Management Canada Research Institutes CCS Field Research Station (Alberta, Canada), Prior to CO2 Injection

100. Impact of CaSO

Catalog

Books, media, physical & digital resources